vs
Side-by-side financial comparison of Millrose Properties, Inc. (MRP) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Millrose Properties, Inc. is the larger business by last-quarter revenue ($189.5M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). Millrose Properties, Inc. runs the higher net margin — 64.5% vs 1.6%, a 62.9% gap on every dollar of revenue.
Millrose Properties, Inc. is a U.S.-based real estate enterprise primarily focused on the acquisition, ownership, operation, and management of income-generating multi-family residential assets. Its core markets span the U.S. Mid-Atlantic and Southeast regions, and it also offers professional property management services to select third-party property owners.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MRP vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $189.5M | $177.4M |
| Net Profit | $122.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 84.8% | 3.9% |
| Net Margin | 64.5% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | 285.8% | — |
| EPS (diluted) | $0.74 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $189.5M | $196.9M | ||
| Q3 25 | $179.3M | $179.5M | ||
| Q2 25 | $149.0M | $181.1M | ||
| Q1 25 | $82.7M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | — | $168.6M | ||
| Q2 24 | — | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $122.2M | — | ||
| Q3 25 | $105.1M | $5.4M | ||
| Q2 25 | $112.8M | $-4.8M | ||
| Q1 25 | $39.8M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-143.5M | ||
| Q2 24 | — | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 84.8% | 1.2% | ||
| Q3 25 | 85.3% | 3.5% | ||
| Q2 25 | 85.1% | 4.7% | ||
| Q1 25 | 55.2% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 64.5% | — | ||
| Q3 25 | 58.6% | 3.0% | ||
| Q2 25 | 75.7% | -2.7% | ||
| Q1 25 | 48.1% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -85.1% | ||
| Q2 24 | — | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.74 | $0.05 | ||
| Q3 25 | $0.63 | $0.12 | ||
| Q2 25 | $0.68 | $-0.11 | ||
| Q1 25 | $0.39 | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $35.0M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9B | $653.9M |
| Total Assets | $9.3B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $35.0M | $238.4M | ||
| Q3 25 | $242.6M | $246.3M | ||
| Q2 25 | $66.6M | $445.9M | ||
| Q1 25 | $89.5M | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $5.9B | $693.1M | ||
| Q3 25 | $5.9B | $727.2M | ||
| Q2 25 | $5.9B | $757.8M | ||
| Q1 25 | $5.9B | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | — | $749.6M | ||
| Q2 24 | — | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $9.3B | $1.3B | ||
| Q3 25 | $9.0B | $1.3B | ||
| Q2 25 | $8.0B | $1.5B | ||
| Q1 25 | $7.2B | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7B | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 30.05× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $43.7M | ||
| Q3 25 | $123.1M | $60.8M | ||
| Q2 25 | $109.1M | $12.0M | ||
| Q1 25 | $21.3M | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | — | $53.9M | ||
| Q2 24 | — | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 30.05× | — | ||
| Q3 25 | 1.17× | 11.20× | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 0.53× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRP
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
